-
Markets
athexgroup.grAthens Exchange GroupΔιαβάστε περισσότεραTogether for a unified, stronger European capital market.
-
Equities
Sustainable finance2025 Euronext ESG Trends ReportΔιαβάστε περισσότεραA data-driven snapshot of how Euronext-listed companies are advancing their Environmental, Social and Governance (ESG) practices.
-
Indices
Access the white paperInvesting in the future of Europe with innovative indicesΔιαβάστε περισσότεραThe first edition of the Euronext Index Outlook series with a particular focus on the European Strategic Autonomy Index.
-
ETFs
The European market place for ETFsEuronext ETF EuropeΔιαβάστε περισσότεραInvestors benefit from a centralised market place that will not only bring transparency but also better pricing due to the grouping of liquidity.
- Funds
-
Fixed Income
European Defence BondsGroupe BPCE lists the first bondΔιαβάστε περισσότεραFirst financial institution in Europe to issue a bond dedicated to the defence sector
- Structured Products
-
Derivatives
Where European Government Bonds Meet the FutureTrade Mini Bond FuturesΔιαβάστε περισσότεραTrade mini bond futures on main European government bonds
-
Commodities
- Επισκόπηση
- Agricultural quotes
- Power Derivatives
- Milling Wheat derivatives
- Corn derivatives
- Spread contracts
- Rapeseed derivatives
- Durum Wheat derivatives
- Dairy derivatives
- Salmon derivatives
- Container Freight Futures
- Delivery & settlement
- Specifications & arrangements
- Commitments of Traders (CoT) report
- Commodity brokers
Take control of unpredictable dairy pricesEuropean Dairy DerivativesΔιαβάστε περισσότεραFutures and options on butter and skimmed milk powder now trading.
-
Resources
Designed to help students navigate the complexities of financial marketsEuronext Trading gameΔιαβάστε περισσότεραJoin the Euronext Trading Game and step into capital markets. Learn from today’s leaders, explore sustainable opportunities, and trade with confidence.
Novartis targets 5% annual sales growth through 2031
LONDON, Nov 19 (Reuters) - Swiss drugmaker Novartis on Thursday outlined new mid-term sales targets that were at the lower end of the range it had given a year earlier, ahead of its annual investor event in London. Novartis now expects net sales to grow 5% annually at constant currencies from 2026 through 2031. Previously, the company expected sales growth of 5%-6% through 2030.
(Reporting by Bhanvi Satija and Marleen KaesebierEditing by Dave Graham)
Find it fast
Looking for more insights? Explore our other news sections for updates on sustainable finance, companies and financial education